Defence Therapeutics Announces Debenture Units Financing

Core Viewpoint - Defence Therapeutics Inc. is conducting a non-brokered private placement of debenture units to raise up to $1,200,000, aimed at enhancing its drug delivery technologies [1][2]. Financing Details - The offering consists of debenture units priced at $1,000 each, with a total gross proceeds target of $1,200,000 [1]. - Each unit includes one $1,000 principal amount of an 8.0% convertible debenture and 1,666 common share purchase warrants [1][2]. - The debentures will bear an interest rate of 8.0% per annum and will mature two years from the issue date [2]. - The principal amount of each debenture is convertible into common shares at a conversion price of $0.60 per share [2]. - Accrued interest can be paid annually in shares at the conversion price or in cash at the company's discretion [2]. Warrant Details - Each warrant allows the holder to acquire one common share at an exercise price of $0.75 for a period of two years from the issue date [3]. Regulatory and Compliance Information - All securities issued will be subject to a statutory hold period of four months and one day following the closing date [4]. - The completion of the offering is contingent upon receiving all necessary regulatory approvals [4]. - The company may pay a finder's fee to eligible arm's length finders in accordance with Canadian Securities Exchange policies [4]. Company Overview - Defence Therapeutics is a clinical-stage biotechnology company focused on developing next-generation antibody-drug conjugates (ADCs) using its proprietary ACCUM® technology, which enhances the precision delivery of ADCs to target cells, thereby increasing efficacy against cancer [6].